Astrocyte Pharmaceuticals Inc.
PrivateLast Round
Series B
Sep 30, 2026
Total Funding Raised
$36.97M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Astrocyte Pharmaceuticals Inc. operates in Healthcare & Life Sciences and is based in Groton, Connecticut. Its latest recorded funding round was a Series B round in September 2026.
Astrocyte Pharmaceuticals Inc. is a biotechnology company developing novel neuroprotective therapeutics for the treatment of stroke, traumatic brain injury, concussions, and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Astrocyte Pharmaceuticals Inc. Comparables
Compare Astrocyte Pharmaceuticals Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NeuroTrauma Sciences | 87% | |
| Owl Therapeutics | 83% | |
| TIBEAY Biosciences | 83% |
For institutional investors. Book with your work email.
Astrocyte Pharmaceuticals Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 30, 2026 | ||||
| Grant | Aug 25, 2026 | ||||
| Grant | Jun 17, 2025 | ||||
| Early Funding | Aug 18, 2023 | ||||
| Grant | Jun 7, 2023 | ||||
Grant | Sep 16, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Astrocyte Pharmaceuticals Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SideCar Angels | Early Funding, Series A, Seed |
| National Institute on Drug Abuse | Grant |
| Dreavent Capital | Early Funding |
| Waterstar Capital | Series B |
| Nest.Bio | Seed, Early Funding |
| CR Ventures | Series A |
| NIH RADx | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 30, 2026
$9.5M round led by DeepWork Capital.
- Aug 25, 2026
$400K grant from National Institute on Drug Abuse and NIH.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 30, 2026
Astrocyte Pharmaceuticals Inc. is advancing AST-004, a novel cerebroprotective therapy targeting astrocytes, through Phase 2 development with potential to become the first therapeutic drug specifically approved to treat concussion and traumatic brain injury.
- receives_financingSep 30, 2026
Astrocyte Pharmaceuticals Inc. completed a $9.5M Series B financing led by DeepWork Capital, with support from existing investors and participation from MintPharma Capital, Waterstar Capital, Dynagrow Capital, and Angel Star Ventures, to advance Phase 2 development of AST-004, including its STARFAST concussion trial, on Sep 30th '26 in Connecticut.
For institutional investors. Book with your work email.
Astrocyte Pharmaceuticals Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Astrocyte Pharmaceuticals Inc.'s valuation, stock price, and market status.
Is Astrocyte Pharmaceuticals Inc. a public or private company?
Astrocyte Pharmaceuticals Inc. is a private company.
What is the current stock price of Astrocyte Pharmaceuticals Inc.?
Astrocyte Pharmaceuticals Inc. is a private company, so its shares have no public market price. Caplight tracks Astrocyte Pharmaceuticals Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Astrocyte Pharmaceuticals Inc. worth (valuation)?
Valuation information for Astrocyte Pharmaceuticals Inc. is not publicly available.
Can I buy Astrocyte Pharmaceuticals Inc. stock?
Astrocyte Pharmaceuticals Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Astrocyte Pharmaceuticals Inc.'s last funding round?
Astrocyte Pharmaceuticals Inc.'s most recent funding round was Series B on September 30, 2026.
Who are the main investors in Astrocyte Pharmaceuticals Inc.?
Key investors in Astrocyte Pharmaceuticals Inc. include Dreavent Capital, DeepWork Capital, Boston Harbor Angels.
Will Astrocyte Pharmaceuticals Inc. IPO soon?
No public IPO plans have been announced for Astrocyte Pharmaceuticals Inc..
How can I track Astrocyte Pharmaceuticals Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Astrocyte Pharmaceuticals Inc.'s shares on secondary markets.